(CKPT), (FBIO) - 3 Penny Stocks To Buy According To Top Stock Market Analysts benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Cadila Healthcare Gains Over 2% After Unit Buys Drug For Menkes Disease Cadila Healthcare said that its US subsidiary has acquired an experimental drug from Cyprium for treating Menkes disease, which is a rare recessive pediatric disease
Updated: February 25, 2021 11:33 am IST
At 11:20 am, the shares of Cadila Healthcare were trading higher by 1.9 per cent on BSE
Cadila Healthcare shares rose more than 2 per cent in mid-morning trading after the pharma company said its US subsidiary has acquired an experimental drug from Cyprium for treating Menkes disease. At 11:20 am, the shares of Cadila Healthcare were trading at Rs 442.50, higher by 1.9 per cent, on the BSE. The shares have touched an intra-day high of Rs 444.70 and a low of Rs 436.35 thus far.
Cadila Healthcare gained 1.97% to Rs 442.45 after the drug maker said it received a final approval from the US drug regulator to market nortriptyline hydrochloride capsules 10 mg, 25 mg, 50 mg and 75 mg.The medication is used to treat mental/mood problems such as depression. The drug will be manufactured at the group s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 313 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Separately, Cadila Healthcare announced that its US subsidiary has acquired experimental drug from Cyprium for treating Menkes disease. Cyprium Therapeutics, a partner of Fortress Biotech, and Sentynl Therapeutics, a US- based specialty pharmaceutical company owned by the Zydus Group, has announced its execution of an asset purchase agreement to commit development funding for and acquire Cyprium s proprietary rights to CUTX-101, its Copper Histidinate product candidate for the treatme
Cadila Healthcare rose 1.12% to Rs 438.75 after the pharmaceutical company said that its US subsidiary has acquired experimental drug from Cyprium for treating Menkes disease.
Cyprium Therapeutics, a partner of Fortress Biotech, and Sentynl Therapeutics, a U.S.- based specialty pharmaceutical company owned by the Zydus Group, has announced its execution of an asset purchase agreement to commit development funding for and acquire Cyprium s proprietary rights to CUTX-101, its Copper Histidinate product candidate for the treatment of Menkes disease.
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of copper transporter ATP7A. CUTX-101 is in clinical development to treat patients with Menkes disease.
Barometers pare gains; Nifty holds 15,000 business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.